Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Valerie ReliasIlene Galinsky

Abstract

Acute myeloid leukemia (AML) is primarily a disease of older adults. These patients may not be candidates for intensive treatment, and there has been an ongoing need for treatment options for this group. We review the use of glasdegib, a hedgehog-pathway inhibitor available for use in combination with low-dose cytarabine (LDAC).Data Sources: PubMed and relevant congress abstracts were searched using the term "glasdegib". In addition, based on our experience with glasdegib, we considered treatment aspects of particular relevance to pharmacists and advanced practitioners.Data Summary: In a randomized phase II study, the combination of glasdegib plus LDAC demonstrated superior overall survival versus LDAC alone (hazard ratio 0.51, 80% confidence interval 0.39-0.67, p = 0.0004). The trial reported adverse events (AEs) of special relevance for older patients, such as hematologic events, gastrointestinal toxicity, and fatigue, as well as AEs associated with Hh-pathway inhibitors (alopecia, muscle spasms, dysgeusia). Educating patients about typical AEs can facilitate adherence as well as early AE identification and proactive management. For LDAC, which is a long-established therapy in AML, various stages of delivery need consideratio...Continue Reading

References

Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amanda F CashenJohn F DiPersio
Oct 2, 2012·Clinical Journal of Oncology Nursing·Marlene K Wilken, Bernadette A Satiroff
Jul 11, 2013·Blood·Alan K BurnettUNKNOWN UK National Cancer Research Institute AML Working Group
Nov 17, 2017·Blood·Gregory A Abel, Heidi D Klepin
Mar 1, 2018·British Journal of Clinical Pharmacology·M Naveed ShaikRobert R LaBadie
Jul 11, 2018·Cancers·Kah Poh Loh, Heidi D Klepin
Feb 5, 2019·Current Medical Research and Opinion·Bruno C MedeirosL Elise Horvath Walsh
May 9, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kelly J NorsworthyRichard Pazdur

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.